AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33331182
Drug: Sitafloxacin 100-mg
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitafloxacin 100-mg once-daily for 3-5 days (acute uncomplicated UTI)
Trial: 33331182
Drug: Sitafloxacin 100-mg
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitafloxacin 100-mg twice daily for 10-14 days (complicated UTI)
Trial: 33331182
Drug: Levofloxacin 500-mg
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500-mg once-daily for 3-5 days (acute uncomplicated UTI)
Trial: 33331182
Drug: Levofloxacin 500-mg
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500-mg once-daily for 10-14 days (complicated UTI)
Trial: 35995816
Drug: Antithrombin administration
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin administration to maintain a level of 80-120%
Trial: 36418930
Drug: Both smokers
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both smokers and nonsmokers (before and after treatment)
Trial: 34637519
Drug: RSV stabilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV stabilized prefusion F subunit vaccine (RSVpreF) with Tdap
Trial: 32342642
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (5 g/day containing 2 g/day eicosapentaenoic acid and 1 g/day docosahexaenoic acid)
Trial: 32342642
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (OO) supplementation (5 g/day)
Trial: 33091706
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (MB) 2 mg/kg intravenous infusion
Trial: 32329887
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus aromatherapy
Trial: 616866158
Drug: Active video
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active video gaming using a motion-controlled video console (Nintendo Wii) for a minimum of 30 minutes a day, 5 days a week, plus weekly Internet-based coaching sessions
Trial: 34229729
Drug: Recombinant erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant erythropoietin (EPREX) 300 units/Kg or 4000 IU subcutaneous injection three times a day for 5 days, along with Enoxaparin 1 mg/kg SQ daily.
Trial: 34229729
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) and placebo (distilled water) subcutaneous injection three times a day for 5 days.
Trial: 32386065
Drug: Brand bupropion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand bupropion XL 300 mg
Trial: 32386065
Drug: Generic bupropion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic bupropion XL 300 mg
Trial: 34190167
Drug: Palonosetron-midazolam combination
RxNorm normalized name: palonosetron, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron-midazolam combination therapy (group PM)
Trial: 34190167
Drug: Palonosetron monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron monotherapy (group P)
Trial: 33068301
Drug: Traditional antidiabetic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional antidiabetic therapy (Control, n = 40)
Trial: 35857827
Drug: OP-101 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OP-101 at 4 mg/kg
Trial: 35857827
Drug: OP-101 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OP-101 at 4 and 8 mg/kg
Trial: 35857827
Drug: Pooled OP-101
RxNorm normalized name: OP-101
DrugBank: Acetylcysteine zidrimer (DB16496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled OP-101 treatment arms
Trial: 33813267
Drug: Surgeon-delivered exercise
RxNorm normalized name: sturgeon, unspecified preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgeon-delivered exercise prescription and activity tracker
Trial: 34906747
Drug: Distinct treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distinct treatments in multi-arm trials sharing a control group
Trial: 33421558
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg intravenously every 3 weeks for 16 cycles)
Trial: 33421558
Drug: Atezolizumab (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (840 mg intravenously every 3 weeks for 16 cycles)
Trial: 32313032
Drug: NMDA stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMDA stimulation (250 mg D-cycloserine (DCS))
Trial: 35712942
Drug: Oryzanol tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oryzanol tablets, 20 mg orally, 3 times a day for 4 weeks
Trial: 32546217
Drug: Whey-protein-infused carbohydrate-loading
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey-protein-infused carbohydrate-loading drinks pre-operatively and early oral feeding post-operatively.
Trial: 34144923
Drug: Amikacin liposome
RxNorm normalized name: AMIKACIN LIPOSOME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin liposome inhalation suspension (ALIS) 590 mg once daily for 12 treatment cycles (96 weeks)
Trial: 32822656
Drug: Culprit-only treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culprit-only treatment
Trial: 32506539
Drug: Early cord
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early cord clamping (CC)
Trial: 34167672
Drug: Integral prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integral prasugrel 60-mg loading dose
Trial: 32701118
Drug: Vaginal Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal Testosterone Cream (0.5 g daily for 2 weeks, then 0.5 g 3 times a week for 10 weeks)
Trial: 36057952
Drug: Generic safinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic safinamide tablet (test), 100 mg
Trial: 36057952
Drug: Brand-name safinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand-name safinamide tablet (reference), 100 mg
Trial: 34459033
Drug: Melatonin (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (18 mg in 1 ml of corn oil, injected SC)
Trial: 34459033
Drug: Control (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (1 ml corn oil only)
Trial: 36235788
Drug: DHA/EPA group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA/EPA group (n = 33) - received six 480 mg capsules containing 576 mg DHA and 284 mg EPA per day for 12 weeks
Trial: 33888136
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Lutein and 2 mg Zeaxanthin in safflower oil (Carotenoid group)
Trial: 36190391
Drug: Abaloparatide 80
RxNorm normalized name: ABALOPARATIDE 80MCG/0.04ML PEN 1.56ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abaloparatide 80 μg daily subcutaneous injections
Trial: 34352943
Drug: Ablative CO2
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative CO2 fractional laser (ACFL) treatment
Trial: 34983126
Drug: Adjuvant oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant oral therapy with tadalafil 5 mg and L-arginine 2,500 mg
Trial: 34983126
Drug: Low-intensity extracorporeal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity extracorporeal shock wave therapy (Li-ESWT) alone
Trial: 32088018
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of OPV and RVV
Trial: 33992607
Drug: Sacubitril/valsartan (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (target dose of 400 mg daily)
Trial: 33992607
Drug: Enalapril (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (target dose of 40 mg daily)
Trial: 35085831
Drug: Treatment T
RxNorm normalized name: Lice Treatment Topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment T
Trial: 35085831
Drug: Reference treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference treatment R
Trial: 34793640
Drug: Combination paracetamol
RxNorm normalized name: paracetamol, combinations excl. psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination paracetamol iv (1 g) and ibuprofen iv (800 mg)
Trial: 34793640
Drug: Paracetamol iv
RxNorm normalized name: PARACETAMOL IVAX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol iv only (1 g)
Trial: 34793640
Drug: Ibuprofen iv
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen iv only (800 mg)
Trial: 34793640
Drug: Combination paracetamol
RxNorm normalized name: paracetamol, combinations excl. psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination paracetamol iv and ibuprofen iv
Trial: 34793640
Drug: Paracetamol iv
RxNorm normalized name: PARACETAMOL IVAX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol iv only
Trial: 34793640
Drug: Ibuprofen iv
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen iv only
Trial: 32440977
Drug: Dexamethasone 0.1%
RxNorm normalized name: DEXAMETHASONE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.1% ophthalmic suspension
Trial: 32440977
Drug: Bromfenac 0.09%
RxNorm normalized name: Bromfenac 0.09% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 0.09% ophthalmic solution
Trial: 35555888
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral FeSO4 (150-200 mg) for 8 weeks
Trial: 33871211
Drug: Weekly 300
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly 300 mg azathioprine (n = 40)
Trial: 33871211
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg methotrexate every week (n = 40)
Trial: 33400433
Drug: Two injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections from two planes (Group C)
Trial: 33400433
Drug: Two injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections in one plane (Group E)
Trial: 32964512
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (0.12% chlorhexidine gluconate + 3% sodium bicarbonate + nystatin 5000 U/mL)
Trial: 32198861
Drug: Phenytoin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (20 mg/kg over 20 minutes)
Trial: 32198861
Drug: Valproate (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate (20 mg/kg over 20 minutes)
Trial: 32198861
Drug: Levetiracetam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (20 mg/kg over 20 minutes)
Trial: 32342846
Drug: Mass testing
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass testing and treatment (MTaT) of malaria infections, tested three times per year for two years, treated with dihydroartemisinin-piperaquine.
Trial: 32342846
Drug: Mass testing
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass testing and treatment (MTaT) of malaria infections.
Trial: 36068131
Drug: Vocal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vocal therapy with TENS (12 sessions of 20 min, pulse: 200μs, frequency: 10Hz) followed by vocal exercises (30 min)
Trial: 36068131
Drug: Vocal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vocal therapy with TENS followed by vocal exercises
Trial: 36068131
Drug: Vocal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vocal therapy without TENS
Trial: 34190197
Drug: TXA, systemic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA, systemic, repeated 1 g bolus
Trial: 34190197
Drug: TXA, topically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA, topically intra-articularly, 2 g in 50 mL saline
Trial: 36472034
Drug: Z‐VAD‐FMK (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z‐VAD‐FMK (20 μmol·L(‐1))
Trial: 33200488
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg nanocurcumin daily for 12 weeks
Trial: 34658706
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of microneedling and chemical peeling (MN + CP)
Trial: 33887209
Drug: Low-dose (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose (1.3 µg) plus AF03
Trial: 33887209
Drug: Low-dose (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose (1.3 µg) plus AS03
Trial: 33887209
Drug: High-dose (2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (2.6 µg) plus AF03
Trial: 33887209
Drug: High-dose (2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (2.6 µg) plus AS03
Trial: 33887209
Drug: Unadjuvanted high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unadjuvanted high-dose (2.6 µg)
Trial: 33651033
Drug: Ultrasonic bath
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic bath with a special detergent solution (Group C)
Trial: 34137526
Drug: Empagliflozin 10mg
RxNorm normalized name: EMPAGLIFLOZIN 10MG TAB
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 10mg twice a day
Trial: 33598865
Drug: Anti-TNF-α treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF-α treatments
Trial: 32690472
Drug: DHA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA treatment (2,152 mg of DHA per day)
Trial: 34470656
Drug: DICA Br
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DICA Br supplemented with 30 g/day of mixed nuts (10 g of peanuts, 10 g of cashew, 10 g of Brazil nuts)
Trial: 33181580
Drug: Terbutaline (5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (5-15 mg)
Trial: 33181580
Drug: Imipramine (30-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (30-150 mg)
Trial: 34687483
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine solution
Trial: 35096742
Drug: Nomogram for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram for cancer-specific survival (CSS) based on independent prognostic factors (age, race, T stage, histological grade, surgery, radiotherapy, chemotherapy)
Trial: 32045673
Drug: Indacaterol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol 150 μg with 9 g charcoal (charcoal-block condition)
Trial: 32045673
Drug: Indacaterol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol 150 μg without charcoal (non-block condition)
Trial: 32708971
Drug: Bridging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging therapy with r-tPA (bolus, partial dose, or full dose)
Trial: 32708971
Drug: Full r-tPA
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full r-tPA dose
Trial: 36363493
Drug: Continuous cold
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous cold flow (CCF) therapy
Trial: 36363493
Drug: Cold pack
RxNorm normalized name: CVS Cold Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold pack (gel ice)
Trial: 34116715
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2 therapy
Trial: 32446164
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (AEDs) treatment including levetiracetam (LEV), valproic acid (VA), and carbamazepine.
Trial: 33899292
Drug: delta-tocotrienol (δT3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delta-tocotrienol (δT3) supplementation 250 mg once daily for 24 weeks
Trial: 33899292
Drug: Placebo (cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose soft gel capsule)
Trial: 33381204
Drug: Manipulative acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulative acupuncture (acupoints acupuncture combined with manipulations of twirling, lifting, and thrusting treatments)
Trial: 33381204
Drug: Simple acupuncture
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple acupuncture (acupoints acupuncture therapy alone)
Trial: 35672832
Drug: E-HELD intervention
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E-HELD intervention (therapist-guided Internet-based cognitive-behavioral therapy)
Trial: 32152326
Drug: T1 (2.5 g/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T1 (2.5 g/L foliar application twice at nursery with a one‐week interval)
Trial: 35798020
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g prunes
Trial: 33739437
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (12 weeks, twice weekly)
Trial: 33479274
Drug: Antibiotics administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics administered in the first 48 hours after birth
Trial: 33479274
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics administered in the first 48 hours after birth
Trial: 32006180
Drug: Engagement in
RxNorm normalized name: Bispecific t-cell engager antibody regn4018
DrugBank: Ubamatamab (DB18875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engagement in discussions on disease experiences, medications, social lives, online resources on RA, frustrations, messages of encouragement, and satirical depictions of their disease experience.
Trial: 35567778
Drug: Early autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early autologous hematopoietic cell transplantation (AHCT) with post‐transplant maintenance therapy
Trial: 34390604
Drug: Enriched RS2
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enriched RS2 cookies (16 g d-1 of Hi-Maize 260, Ingredion) for 4 weeks
Trial: 34178124
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg intramuscular neridronate given once daily for 16 consecutive days
Trial: 33246494
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT), 30–40 treatment sessions in a high pressure chamber (2.4 atmospheres absolute) inhaling 100% oxygen through a mask.
Trial: 32043986
Drug: Dexamethasone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (20 mg IV once daily from day 1 to day 5, then 10 mg IV once daily from day 6 to day 10)
Trial: 33971353
Drug: Brolucizumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brolucizumab (3 or 6 mg)
Trial: 33971353
Drug: Brolucizumab therapy
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brolucizumab therapy continued after first IOI-related AE
Trial: 33971353
Drug: Brolucizumab therapy
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brolucizumab therapy not continued after first IOI-related AE
Trial: 33971353
Drug: Brolucizumab injections
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brolucizumab injections before first IOI-related AE
Trial: 35325834
Drug: Low crude
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low crude fiber diet (30 g/kg CF)
Trial: 34484379
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of hydrocortisone (50 mg/6 h, intravenously), Vitamin C (1.5 g/6 h in 100 ml normal saline or DW5%, intravenously), and thiamine (200 mg/12 h in 50 ml normal saline or DW5%, intravenously)
Trial: 34484379
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of hydrocortisone, thiamine, and Vitamin C
Trial: 33303119
Drug: TMVr plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMVr plus guideline-directed medical therapy (GDMT)
Trial: 36335573
Drug: benzoate 1000
RxNorm normalized name: benzoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benzoate 1000 (500 mg/day for the first 4 weeks, 1000 mg/day from the 5th week)